Edwards Lifesciences Corp (EW) : Weaver C. Barksdale Associates added new position in Edwards Lifesciences Corp during the most recent quarter end. The investment management firm now holds 27,769 shares of Edwards Lifesciences Corp which is valued at $2.9 Million according to a report filed by the company on Apr 5, 2016 with the SEC.Edwards Lifesciences Corp makes up approximately 2.22% of Weaver C. Barksdale Associates’s portfolio.
Other Hedge Funds, Including , Stillwater Investment Management added EW to its portfolio by purchasing 2,488 company shares during the most recent quarter which is valued at $263,703. Edwards Lifesciences Corp makes up approx 0.16% of Stillwater Investment Management’s portfolio.
On the company’s financial health, Edwards Lifesciences Corp reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.60. The company had revenue of $671.10 million for the quarter, compared to analysts expectations of $651.30 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Leerink Partners on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .Company shares were Reiterated by Canaccord Genuity on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $95 .Company shares were Reiterated by RBC Capital Mkts on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 110 from a previous price target of $100 .
Edwards Lifesciences Corp opened for trading at $105.19 and hit $107.58 on the upside on Monday, eventually ending the session at $105.99, with a gain of 1.45% or 1.52 points. The heightened volatility saw the trading volume jump to 15,78,702 shares. Company has a market cap of $22,745 M.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.